NCT05436288 - A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 22, 2022

Study Completion Date

January 22, 2023

Conditions

Persistent Corneal Epithelial Defect

Interventions

DRUG

KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)

KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.

Trial Locations (1)

06800

Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City